MannKind Corp. (MNKD)

[TREND1]

MannKind: Years Before Achieving Break-Even Point
Looking For Diogenes

•Readers will see the futility that MannKind is facing with their prescription stagnation issues.

•MannKind's promises versus what they have actually accomplished for investors will be contrasted.

•107 weeks and more than 2 years marketing Afrezza the barriers continue to grow for MannKind.



http://seekingalpha.com/article/4050047-mannkind-empty-saddles-empty-promises?app=1&auth_param=1vat:1cb8kvn:d4e154e034c1c5bb880c52d360a79bdc&uprof=51#alt3